Clinical Trials Directory

Trials / Completed

CompletedNCT00993824

Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

Use of Continuous Glucose Monitoring With Ambulatory Glucose Profile Analysis to Demonstrate the Glycemic Effect of Colesevelam HCl (Welchol) in Patients With Type 2 Diabetes

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
21 (actual)
Sponsor
HealthPartners Institute · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to obtain continuous glucose monitoring (CGM) data from individuals taking Welchol compared to placebo. The CGM data will determine the effect on glucose control of adding Welchol to an anti-diabetic medication regimen.

Detailed description

To understand the effect of the addition of colesevelam HCl to oral agent therapy in individuals with type 2 diabetes on glycemic control by utilizing a novel technology, continuous glucose monitoring with ambulatory glucose profile analysis. To date there are no studies of this compound that have employed continuous glucose monitoring (CGM) with ambulatory glucose profile (AGP) analysis to obtain data that will detail the diurnal glucose patterns associated with this therapy. We plan to employ CGM at critical points throughout the study. AGP analysis will enable rapid assessment of the clinical status of the subject. Using statistically stable estimates of hourly values represented by five percentile curves AGP depicts glucose exposure, variability and stability. Previously, we have used AGP analysis to characterize glucose perturbations in individuals ranging from normal glucose tolerance to overt type 2 diabetes.

Conditions

Interventions

TypeNameDescription
DRUGcolesevelam HCl3.75 grams of colesevelam HCl (6 tablets)
DRUGplacebo

Timeline

Start date
2009-09-01
Primary completion
2011-09-01
Completion
2011-09-01
First posted
2009-10-14
Last updated
2015-11-30
Results posted
2014-06-17

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00993824. Inclusion in this directory is not an endorsement.